Norbert Kraut: Celebrating the Approval of Our Treatment for People with HER2-Mutant Advanced NSCLC
Norbert Kraut, Senior Executive Scientist at Boehringer Ingelheim, shared a post by Boehringer Ingelheim, adding:
“Science drives progress, and today we celebrate a major milestone: the approval of our treatment for people with HER2-mutant advanced non-small cell lung cancer (NSCLC). This achievement reflects years of rigorous research, innovative approaches, and a deep commitment to understanding disease mechanisms. A heartfelt thank you to our teams for their dedication to advancing oncology research and delivering meaningful solutions for patients. Together, we continue to push boundaries and transform lives for generations.”
Quoting Boehringer Ingelheim‘s post:
“NEWS for media: Our targeted cancer therapy has been approved in the U.S. for people with HER2 (ERBB2)-mutant advanced non-small cell lung cancer.
Learn more here.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023